<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40844815</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-9891</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>The American journal of drug and alcohol abuse</Title><ISOAbbreviation>Am J Drug Alcohol Abuse</ISOAbbreviation></Journal><ArticleTitle>Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00952990.2025.2541212</ELocationID><Abstract><AbstractText><i>Background:</i> Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due in part to the very high rates of co-morbid depression in people with OUD, as depression can drive opioid use. Therefore, administering a rapid-acting antidepressant such as ketamine early in a treatment attempt may be an effective strategy to improve outcomes.<i>Objectives:</i> Here, we describe a case series of three patients (two males, one female) diagnosed with OUD initiating methadone treatment and endorsing symptoms of depression, who met criteria for a single-arm open-label feasibility trial (NCT05051449) at an opioid treatment program in Baltimore, Maryland.<i>Methods:</i> Participants underwent a 2-week ketamine regimen (0.5&#x2009;mg/kg infusion over 40 min, three times per week for 2&#xa0;weeks).<i>Results:</i> Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. All three patients remained in treatment through the 3-month timepoint with strong treatment adherence. With treatment, self-reported depression symptoms decreased from severe to mild/moderate in two patients, and from moderate to remission in the third.<i>Conclusions:</i> Randomized controlled trials are warranted to test whether ketamine may be a feasible and safe adjunctive treatment for OUD in patients initiating methadone treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manza</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0791-357X</Identifier><AffiliationInfo><Affiliation>Kahlert Institute for Addiction Medicine, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belcher</LastName><ForeName>Annabelle M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-4194-0181</Identifier><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzsimons</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spaderna</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenblatt</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Hannah C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derenoncourt</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Center, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gann</LastName><ForeName>Donald</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farooq</LastName><ForeName>Umer</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kvarta</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Maryland Psychiatric Research Center, Departments of Psychiatry and Physiology, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiPaula</LastName><ForeName>Bethany A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merritt</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lifestream Health Center, Bowie, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Baltimore Ketamine Clinic, Sparks, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gould</LastName><ForeName>Todd D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Pharmacology, Anatomy &amp; Neurobiology University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs Maryland Health Care System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kattakuzhy</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Pharmacology, Anatomy &amp; Neurobiology University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs Maryland Health Care System, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Care and Research, Institute of Human Virology, Division of Infectious Disease, University of Maryland Baltimore, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Drug Alcohol Abuse</MedlineTA><NlmUniqueID>7502510</NlmUniqueID><ISSNLinking>0095-2990</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Opioid addiction</Keyword><Keyword MajorTopicYN="N">antidepressant</Keyword><Keyword MajorTopicYN="N">autobiographies</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">medications for opioid use disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844815</ArticleId><ArticleId IdType="doi">10.1080/00952990.2025.2541212</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>